Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Belsomra (suvorexant) is indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
• This summary is based on the review of 15 systematic review(s)/meta-analysis(es). ^[1-15]
• Suvorexant (20 mg and 40 mg) and daridorexant (10 mg and 50 mg) showed the most significant reduction in Latency to Persistent Sleep (LPS).
• Lemborexant (5 mg and 10 mg) was the most effective for reducing Subjective Sleep Onset Time (sTSO).
• Suvorexant 40 mg and lemborexant 10 mg may have been the most effective for increasing Total Sleep Time (TST), particularly subjective TST (sTST).
• Suvorexant (OR = 0.30) and suvorexant combined with ramelteon (OR = 0.39) reduced the incidence of delirium in adult hospitalized patients.
• Common adverse effects associated with insomnia treatments included somnolence, fatigue, abnormal dreams, and dry mouth, with higher doses of suvorexant (40 mg and 80 mg) showing increased safety risks (RR 1.09 and 1.65, respectively).
• No significant differences were observed in severe adverse events between suvorexant and placebo, except for instances of somnolence and excessive daytime sleepiness, with no significant differences in the rates of hallucinations, suicidal ideation/behavior, or motor vehicle accidents.
• Lemborexant demonstrated a lower incidence of adverse effects compared to higher doses of suvorexant, with no significant driving performance impairment noted for lemborexant.
• Insomnia treatments are effective and safe for older adults, with suvorexant improving sleep maintenance with mild side effects, making it suitable for this population. Suvorexant, with or without ramelteon, effectively reduces delirium incidence in elderly hospitalized patients and benefits patients with Alzheimer's disease by increasing total sleep time and sleep efficiency while reducing wake after sleep onset time.